EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy

Joshua S Friedman, Benjamin H Durham, Anne S Reiner iD, Mariko Yabe, Kseniya Petrova-Drus, Ahmet Dogan, Melissa Pulitzer, Klaus J Busam, Jasmine H Francis, Raajit K Rampal, Gary A Ulaner, Ryan Reddy und 19 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19462 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Joshua S Friedman und 30 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Neurology, Neurosurgery, and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Mutation, Erdheim-Chester Disease. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai–Dorfman–Destombes disease (RDD) and Erdheim–Chester disease (ECD), and these have been characterized with respect to clinical phenotypes, driver mutations and treatment paradigms. Less is known about patients with mixed histiocytic neoplasms (MXH), that is two or more coexisting disorders. This international collaboration examined patients with biopsy‐proven MXH with respect to component disease subtypes, oncogenic driver mutations and responses to conventional (chemotherapeutic or immunosuppressive) versus targeted (BRAF or MEK inhibitor) therapies. Twenty‐seven patients were studied with ECD/LCH (19/27), ECD/RDD (6/27), RDD/LCH (1/27) and ECD/RDD/LCH (1/27). Mutations previously undescribed in MXH were identified, including KRAS, MAP2K2, MAPK3, non‐V600‐BRAF, RAF1 and a BICD2‐BRAF fusion. A repeated‐measure generalized estimating equation demonstrated that targeted treatment was statistically significantly (1) more likely to result in a complete response (CR), partial response (PR) or stable disease (SD) (odds ratio [OR]: 17.34, 95% CI: 2.19–137.00, p = 0.007), and (2) less likely to result in progression (OR: 0.08, 95% CI: 0.03–0.23, p < 0.0001). Histiocytic neoplasms represent an entity with underappreciated clinical and molecular diversity, poor responsiveness to conventional therapy and exquisite sensitivity to targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationErdheim-Chester DiseaseHumansMaleFemaleAdultMiddle AgedAgedAdolescentMolecular Targeted TherapyYoung AdultHistiocytosis, Langerhans-CellChildHistiocytosis, SinusProto-Oncogene Proteins B-rafProtein Kinase InhibitorsChild, Preschool

Stichwörter der Autor:innen

MAPK signallinghistiocytesmyeloid neoplasmtargeted therapy

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsBRAF protein, human

Autor:innen und Institutionen

  • Departments of Neurology, Neurosurgery, and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Molecular Pharmacology, Sloan Kettering Institute, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Anne S Reiner, Roei D Mazor, Oshrat Hershkovitz-Rokah, Gaurav Goyal, Jithma P Abeykoon, Eli L Diamond

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Cancer Institute
  • National Center for Advancing Translational Sciences

Zitieren

APA

Friedman, J. S., Durham, B. H., Reiner, A. S., Yabe, M., Petrova-Drus, K., Dogan, A., Pulitzer, M., Busam, K. J., Francis, J. H., Rampal, R. K., Ulaner, G. A., Reddy, R., Yeh, R., Hatzoglou, V., Lacouture, M. E., Rotemberg, V., Mazor, R. D., Hershkovitz-Rokah, O., Shpilberg, O., …, & Diamond, E. L. (2024). Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy. British Journal of Haematology. https://doi.org/10.1111/bjh.19462

Vancouver

Friedman JS, Durham BH, Reiner AS, Yabe M, Petrova-Drus K, Dogan A, et al. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy. British Journal of Haematology. 2024. doi:10.1111/bjh.19462

BibTeX
@article{Friedman2024,
  author = {Friedman, Joshua S and Durham, Benjamin H and Reiner, Anne S and Yabe, Mariko and Petrova-Drus, Kseniya and Dogan, Ahmet and Pulitzer, Melissa and Busam, Klaus J and Francis, Jasmine H and Rampal, Raajit K and Ulaner, Gary A and Reddy, Ryan and Yeh, Randy and Hatzoglou, Vaios and Lacouture, Mario E and Rotemberg, Veronica and Mazor, Roei D and Hershkovitz-Rokah, Oshrat and Shpilberg, Ofer and Goyal, Gaurav and Go, Ronald S and Abeykoon, Jithma P and Rech, Karen and Morlote, Diana and Fidai, Shiraz and Gannamani, Vedavyas and Zia, Maryam and Abdel-Wahab, Omar and Panageas, Katherine S and Rosenblum, Marc K and Diamond, Eli L},
  title = {Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19462}
}
Kostenlos starten →